Alnylam Pharmaceuticals, Inc. (ALNY)
224.03
-3.25
(-1.43%)
USD |
NASDAQ |
Oct 23, 16:00
223.90
-0.13
(-0.06%)
After-Hours: 20:00
Alnylam Pharmaceuticals Enterprise Value : 29.64B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 29.64B |
| October 22, 2026 | 30.07B |
| October 21, 2026 | 29.78B |
| October 20, 2026 | 30.53B |
| October 19, 2026 | 30.88B |
| October 16, 2026 | 30.68B |
| October 15, 2026 | 30.98B |
| October 14, 2026 | 29.70B |
| October 13, 2026 | 29.61B |
| October 12, 2026 | 30.04B |
| October 09, 2026 | 30.80B |
| October 08, 2026 | 29.71B |
| October 07, 2026 | 29.69B |
| October 06, 2026 | 29.63B |
| October 05, 2026 | 29.09B |
| October 02, 2026 | 29.06B |
| October 01, 2026 | 30.60B |
| September 30, 2026 | 32.68B |
| September 29, 2026 | 33.66B |
| September 28, 2026 | 33.83B |
| September 25, 2026 | 33.91B |
| September 24, 2026 | 33.06B |
| September 23, 2026 | 32.65B |
| September 22, 2026 | 33.33B |
| September 21, 2026 | 32.35B |
| Date | Value |
|---|---|
| September 18, 2026 | 31.72B |
| September 17, 2026 | 32.51B |
| September 16, 2026 | 31.69B |
| September 15, 2026 | 31.54B |
| September 14, 2026 | 33.11B |
| September 11, 2026 | 32.94B |
| September 10, 2026 | 32.78B |
| September 09, 2026 | 34.18B |
| September 08, 2026 | 34.46B |
| September 04, 2026 | 35.27B |
| September 03, 2026 | 35.05B |
| September 02, 2026 | 35.44B |
| September 01, 2026 | 32.59B |
| August 31, 2026 | 31.87B |
| August 28, 2026 | 31.39B |
| August 27, 2026 | 31.32B |
| August 26, 2026 | 31.64B |
| August 25, 2026 | 31.79B |
| August 24, 2026 | 31.24B |
| August 21, 2026 | 31.27B |
| August 20, 2026 | 30.34B |
| August 19, 2026 | 32.12B |
| August 18, 2026 | 30.25B |
| August 17, 2026 | 29.72B |
| August 14, 2026 | 30.26B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ionis Pharmaceuticals, Inc. | 7.245B |
| Vertex Pharmaceuticals, Inc. | 126.85B |
| BridgeBio Pharma, Inc. | 16.08B |
| Pfizer Inc. | 222.94B |
| Regeneron Pharmaceuticals, Inc. | 77.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 164.49M |
| Revenue (Quarterly) | 1.291B |
| Total Expenses (Quarterly) | 1.126B |
| EPS Diluted (Quarterly) | 1.207 |
| Gross Profit Margin (Quarterly) | 76.88% |
| Profit Margin (Quarterly) | 12.74% |
| Earnings Yield | 2.64% |
| Operating Earnings Yield | 3.24% |
| Normalized Earnings Yield | 2.569 |